The MOOP-CAD study program characterizes, for the first time, the pathophysiological processes and molecular mechanisms of coronary atherosclerotic plaque progression by combining in vivo intravascular imaging techniques with circulating immune single-cell multi-omics analysis. In this study, the investigators evaluate the imaging characteristics of coronary plaques by optical coherence tomography (OCT) and invasive angiography, and study the correlation between plaque characteristics and the multi-omics immune characteristic profiles.
Male or female, Age ≥ 18 years and ≤ 85 years.
Ability to understand the requirements of the study and to provide informed consent.
Have been clinically stable for at least 6 months.
Presence of ≥1 lesion with angiographic diameter stenosis >50% with no TCFA lesions in the most severely narrowed native coronary artery (target vessel). TCFA was defined as a lipidic plaque with the thinnest FCT <75 mm and maximum lipid arc >180°.
Cardiogenic shock or circulatory depression，life-threatening arrhythmia.
Known systolic heart failure with LVEF ≤30%.
Severe systemic diseases (end-stage renal disease, serious liver dysfunction, chronic active inflammatory diseases, active oncologic diseases, autoimmune diseases).
Septicemia, acute inflammatory event with fever.
Subjects who meet the preset inclusion criteria for each group of people, understand the research requirements and treatment procedures, and sign the informed consent.
Cohort
Prospective
Not listed
Incidence of MACE
The incidence of major adverse cardiovascular events in patients (Major adverse cardiovascular events is defined as the composite of all-cause death, recurrent myocardial infarction, revascularization, unplanned readmission for angina exacerbation or unstable angina)
Incidence of SCD
The incidence of sudden cardiac death in patients
Incidence of nonfatal myocardial infarction
The incidence of nonfatal myocardial infarction in patients
Incidence of target vessel revascularization
The incidence of target vessel revascularization in patients
Click on the lead sponsor to view all of their trials.
